Hikma Pharmaceuticals (LON:HIK)‘s stock had its “neutral” rating restated by research analysts at JPMorgan Chase & Co. in a report issued on Monday.

Several other analysts have also recently weighed in on the stock. Jefferies Group cut shares of Hikma Pharmaceuticals to an “underperform” rating and decreased their price objective for the stock from GBX 1,074 ($14.56) to GBX 895 ($12.14) in a research note on Wednesday, January 10th. Numis Securities reaffirmed a “buy” rating and set a GBX 1,300 ($17.63) price objective on shares of Hikma Pharmaceuticals in a research note on Wednesday, December 20th. Morgan Stanley reaffirmed an “equal weight” rating and set a GBX 1,100 ($14.92) price objective on shares of Hikma Pharmaceuticals in a research note on Friday, December 1st. Peel Hunt reaffirmed a “hold” rating and set a GBX 1,390 ($18.85) price objective on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 15th. Finally, decreased their price objective on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.37) to GBX 865 ($11.73) and set a “reduce” rating on the stock in a research note on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. Hikma Pharmaceuticals currently has an average rating of “Hold” and an average price target of GBX 1,171 ($15.88).

Hikma Pharmaceuticals (HIK) traded down GBX 1.50 ($0.02) on Monday, reaching GBX 1,012 ($13.72). 186,466 shares of the company’s stock traded hands, compared to its average volume of 720,152. The firm has a market capitalization of $2,430.00 and a price-to-earnings ratio of 2,024.00. Hikma Pharmaceuticals has a 12 month low of GBX 906.50 ($12.29) and a 12 month high of GBX 2,346 ($31.81).

COPYRIGHT VIOLATION WARNING: “JPMorgan Chase & Co. Reaffirms Neutral Rating for Hikma Pharmaceuticals (HIK)” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/15/jpmorgan-chase-co-reaffirms-neutral-rating-for-hikma-pharmaceuticals-hik.html.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.